Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 2/2015

01.03.2015 | Clinical Investigation

Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy

verfasst von: Tomoaki Higashiyama, Yasuhiro Nishida, Katsutaro Morino, Satoshi Ugi, Yoshihiko Nishio, Hiroshi Maegawa, Masahito Ohji

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To quantitatively evaluate the efficacy of methylprednisolone pulse therapy for extraocular muscle inflammation in thyroid-associated ophthalmopathy (TAO) using the short-tau inversion-recovery (STIR) technique of magnetic resonance imaging (MRI).

Methods

The signal intensities of the superior rectus (SR), inferior rectus (IR), lateral rectus (LR), medial rectus (MR), and superior oblique (SO) muscles were measured using the STIR images from 34 eyes of 17 patients with TAO before and after methylprednisolone pulse therapy and 19 eyes of 19 controls. The signal intensity ratio (SIR) of the signal intensity in muscles to that in brain white matter was calculated.

Results

The mean SIRs of the controls were 1.08 ± 0.26 in the SR, 1.32 ± 0.29 in the IR, 1.34 ± 0.19 in the LR, 1.47 ± 0.25 in the MR, and 1.28 ± 0.22 in the SO muscles. SIRs exceeding 2.0 were out of the normal range. The SIRs of the patients with TAO before treatment were 2.19 ± 0.64, 2.44 ± 0.58, 1.96 ± 0.43, 2.24 ± 0.47, and 1.91 ± 0.42, respectively, which was significantly (P < 0.001) higher than those of the controls; after treatment, the mean SIRs were 1.82 ± 0.57, 1.81 ± 0.49, 1.64 ± 0.35, 1.88 ± 0.43, and 1.54 ± 0.33, respectively, significantly (P < 0.001) lower in all muscles than those before treatment. However, the SIRs of some muscles remained over 2.0. Moreover, all cases that had deterioration of TAO had one or more muscles with a SIR exceeding 2.5 after treatment.

Conclusion

Extraocular muscle inflammation in TAO improved with treatment. However, inflammation in some muscles persisted after treatment, and a high SIR in the muscle after treatment suggested the risk of deterioration of TAO.
Literatur
1.
Zurück zum Zitat Weetman AP, McGregor AM, Hall R. Ocular manifestations of Graves’ disease: a review. J R Soc Med. 1984;77:936–42.PubMedCentralPubMed Weetman AP, McGregor AM, Hall R. Ocular manifestations of Graves’ disease: a review. J R Soc Med. 1984;77:936–42.PubMedCentralPubMed
2.
Zurück zum Zitat Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med. 1993;329:1468–75.CrossRefPubMed Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med. 1993;329:1468–75.CrossRefPubMed
3.
4.
6.
Zurück zum Zitat Dandona P, Marshall NJ, Bidey SP, Nathan A, Havard CW. Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis. Br Med J. 1979;1:374–6.CrossRefPubMedCentralPubMed Dandona P, Marshall NJ, Bidey SP, Nathan A, Havard CW. Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis. Br Med J. 1979;1:374–6.CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Bigos ST, Nisula BC, Daniels GH, Eastman RC, Johnston HH, Kohler PO. Cyclophosphamide in the management of advanced Graves’ ophthalmopathy. A preliminary report. Ann Intern Med. 1979;90:921–3.CrossRef Bigos ST, Nisula BC, Daniels GH, Eastman RC, Johnston HH, Kohler PO. Cyclophosphamide in the management of advanced Graves’ ophthalmopathy. A preliminary report. Ann Intern Med. 1979;90:921–3.CrossRef
8.
Zurück zum Zitat Weetman AP, McGregor AM, Ludgate M, Beck L, Mills PV, Lazarus JH, et al. Cyclosporin improves Graves’ ophthalmopathy. Lancet. 1983;2:486–9.CrossRefPubMed Weetman AP, McGregor AM, Ludgate M, Beck L, Mills PV, Lazarus JH, et al. Cyclosporin improves Graves’ ophthalmopathy. Lancet. 1983;2:486–9.CrossRefPubMed
9.
Zurück zum Zitat Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989;321:1353–9.CrossRefPubMed Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med. 1989;321:1353–9.CrossRefPubMed
10.
Zurück zum Zitat Hiromatsu Y, Tanaka K, Sato M, Kuroki T, Nonaka K, Kojima K, et al. Intravenous methylprednisolone pulse therapy for Graves’ ophthalmopathy. Endocr J. 1993;40:63–72.CrossRefPubMed Hiromatsu Y, Tanaka K, Sato M, Kuroki T, Nonaka K, Kojima K, et al. Intravenous methylprednisolone pulse therapy for Graves’ ophthalmopathy. Endocr J. 1993;40:63–72.CrossRefPubMed
11.
Zurück zum Zitat Tagami T, Tanaka K, Sugawa H, Nakamura H, Miyoshi Y, Mori T, et al. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy. Endocr J. 1996;43:689–99.CrossRefPubMed Tagami T, Tanaka K, Sugawa H, Nakamura H, Miyoshi Y, Mori T, et al. High-dose intravenous steroid pulse therapy in thyroid-associated ophthalmopathy. Endocr J. 1996;43:689–99.CrossRefPubMed
12.
Zurück zum Zitat Kauppinen-Mäkelin R, Karma A, Leinonen E, Löyttyniemi E, Salonen O, Sane T, et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand. 2002;80:316–21.CrossRefPubMed Kauppinen-Mäkelin R, Karma A, Leinonen E, Löyttyniemi E, Salonen O, Sane T, et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand. 2002;80:316–21.CrossRefPubMed
13.
Zurück zum Zitat Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves’ ophthalmopathy. Jpn J Ophthalmol. 2002;46:563–7.CrossRefPubMed Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves’ ophthalmopathy. Jpn J Ophthalmol. 2002;46:563–7.CrossRefPubMed
14.
Zurück zum Zitat Aktaran S, Akarsu E, Erbağci I, Araz M, Okumuş S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2007;61:45–51.CrossRefPubMed Aktaran S, Akarsu E, Erbağci I, Araz M, Okumuş S, Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2007;61:45–51.CrossRefPubMed
15.
Zurück zum Zitat van Geest RJ, Sasim IV, Koppeschaar HP, Kalmann R, Stravers SN, Bijlsma WR, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves’ orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158:229–37.CrossRefPubMed van Geest RJ, Sasim IV, Koppeschaar HP, Kalmann R, Stravers SN, Bijlsma WR, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves’ orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol. 2008;158:229–37.CrossRefPubMed
16.
Zurück zum Zitat Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639–44.CrossRefPubMedCentralPubMed Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73:639–44.CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–85.CrossRefPubMed Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–85.CrossRefPubMed
18.
Zurück zum Zitat Eidelberg D, Newton MR, Johnson G, MacManus DG, McDonald WI, Miller DH, et al. Chronic unilateral optic neuropathy: a magnetic resonance study. Ann Neurol. 1988;24:3–11.CrossRefPubMed Eidelberg D, Newton MR, Johnson G, MacManus DG, McDonald WI, Miller DH, et al. Chronic unilateral optic neuropathy: a magnetic resonance study. Ann Neurol. 1988;24:3–11.CrossRefPubMed
19.
Zurück zum Zitat Miller DH, Newton MR, van der Poel JC, du Boulay EP, Halliday AM, Kendall BE, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology. 1988;38:175–9.CrossRefPubMed Miller DH, Newton MR, van der Poel JC, du Boulay EP, Halliday AM, Kendall BE, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology. 1988;38:175–9.CrossRefPubMed
20.
Zurück zum Zitat Kermode AG, Moseley IF, Kendall BE, Miller DH, MacManus DG, McDonald WI. Magnetic resonance imaging in Leber’s optic neuropathy. J Neurol Neurosurg Psychiatry. 1989;52:671–4.CrossRefPubMedCentralPubMed Kermode AG, Moseley IF, Kendall BE, Miller DH, MacManus DG, McDonald WI. Magnetic resonance imaging in Leber’s optic neuropathy. J Neurol Neurosurg Psychiatry. 1989;52:671–4.CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K, et al. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid. 1992;2:299–305.CrossRefPubMed Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K, et al. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid. 1992;2:299–305.CrossRefPubMed
22.
Zurück zum Zitat Hoh HB, Laitt RD, Wakeley C, Kabala J, Goddard P, Potts MJ, et al. The STIR sequence MRI in the assessment of extraocular muscles in thyroid eye disease. Eye (Lond). 1994;8:506–10.CrossRef Hoh HB, Laitt RD, Wakeley C, Kabala J, Goddard P, Potts MJ, et al. The STIR sequence MRI in the assessment of extraocular muscles in thyroid eye disease. Eye (Lond). 1994;8:506–10.CrossRef
23.
Zurück zum Zitat Laitt RD, Hoh B, Wakeley C, Kabala J, Harrad R, Potts M, et al. The value of the short tau inversion recovery sequence in magnetic resonance imaging of thyroid eye disease. Br J Radiol. 1994;67:244–7.CrossRefPubMed Laitt RD, Hoh B, Wakeley C, Kabala J, Harrad R, Potts M, et al. The value of the short tau inversion recovery sequence in magnetic resonance imaging of thyroid eye disease. Br J Radiol. 1994;67:244–7.CrossRefPubMed
24.
Zurück zum Zitat Bailey CC, Kabala J, Laitt R, Goddard P, Hoh HB, Potts MJ, et al. Magnetic resonance imaging in thyroid eye disease. Eye (Lond). 1996;10:617–9.CrossRef Bailey CC, Kabala J, Laitt R, Goddard P, Hoh HB, Potts MJ, et al. Magnetic resonance imaging in thyroid eye disease. Eye (Lond). 1996;10:617–9.CrossRef
25.
Zurück zum Zitat Mayer E, Herdman G, Burnett C, Kabala J, Goddard P, Potts MJ. Serial STIR magnetic resonance imaging correlates with clinical score of activity in thyroid eye disease. Eye (Lond). 2001;15:313–8.CrossRef Mayer E, Herdman G, Burnett C, Kabala J, Goddard P, Potts MJ. Serial STIR magnetic resonance imaging correlates with clinical score of activity in thyroid eye disease. Eye (Lond). 2001;15:313–8.CrossRef
26.
Zurück zum Zitat Mayer EJ, Fox DL, Herdman G, Hsuan J, Kabala J, Goddard P, et al. Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol. 2005;56:20–4.CrossRefPubMed Mayer EJ, Fox DL, Herdman G, Hsuan J, Kabala J, Goddard P, et al. Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur J Radiol. 2005;56:20–4.CrossRefPubMed
27.
Zurück zum Zitat Rodríguez-González N, Pérez-Rico C, López-Para Giménez R, Arévalo-Serrano J, Del Amo García B, Calzada Domingo L, et al. Short-tau inversion-recovery (STIR) sequence magnetic resonance imaging evaluation of orbital structures in Graves’ orbitopathy. Arch Soc Esp Oftalmol. 2011;86:351–7.CrossRefPubMed Rodríguez-González N, Pérez-Rico C, López-Para Giménez R, Arévalo-Serrano J, Del Amo García B, Calzada Domingo L, et al. Short-tau inversion-recovery (STIR) sequence magnetic resonance imaging evaluation of orbital structures in Graves’ orbitopathy. Arch Soc Esp Oftalmol. 2011;86:351–7.CrossRefPubMed
28.
Zurück zum Zitat Tortora F, Prudente M, Cirillo M, Elefante A, Belfiore MP, Romano F. Diagnostic accuracy of short-time inversion recovery sequence in Graves’ Ophthalmopathy before and after prednisone treatment. Neuroradiology. 2014;56:353–61.CrossRefPubMed Tortora F, Prudente M, Cirillo M, Elefante A, Belfiore MP, Romano F. Diagnostic accuracy of short-time inversion recovery sequence in Graves’ Ophthalmopathy before and after prednisone treatment. Neuroradiology. 2014;56:353–61.CrossRefPubMed
29.
Zurück zum Zitat Yokoyama N, Nagataki S, Uetani M, Ashizawa K, Eguchi K. Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophthalmopathy. Thyroid. 2002;12:223–7.CrossRefPubMed Yokoyama N, Nagataki S, Uetani M, Ashizawa K, Eguchi K. Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophthalmopathy. Thyroid. 2002;12:223–7.CrossRefPubMed
30.
Zurück zum Zitat Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168–99.PubMed Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168–99.PubMed
31.
Zurück zum Zitat Gerlach M, Ferbert A. Pure eye muscle involvement in endocrine orbitopathy. Eur Neurol. 2008;60:67–72.CrossRefPubMed Gerlach M, Ferbert A. Pure eye muscle involvement in endocrine orbitopathy. Eur Neurol. 2008;60:67–72.CrossRefPubMed
Metadaten
Titel
Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy
verfasst von
Tomoaki Higashiyama
Yasuhiro Nishida
Katsutaro Morino
Satoshi Ugi
Yoshihiko Nishio
Hiroshi Maegawa
Masahito Ohji
Publikationsdatum
01.03.2015
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 2/2015
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-014-0365-x

Weitere Artikel der Ausgabe 2/2015

Japanese Journal of Ophthalmology 2/2015 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.